Enzyme replacement therapy may help treat congenital form of ricketsMay 31st, 2008 - 1:37 pm ICT by admin
Washington , May 31 (ANI): In a study on mice, researchers at the Burnham Institute for Medical Research have successfully discovered that enzyme replacement therapy may act as a potential treatment for preventing hypophosphatasia (HPP), a primary skeletal disease of genetic origin.
Headed by Jose Luis Millan, Ph.D., the discovery may trigger future clinical trials for HPP patients.
Rickets is a softening of the bones resulting from a lack of vitamin D or calcium and from insufficient exposure to sunlight. Hypophosphatasia is a rare, heritable form of rickets caused by mutations in a gene called TNAP, which is essential for the process that causes minerals such as calcium and phosphorus to be deposited in developing bones and teeth.
The characteristics of Hypophosphatasia can vary depending on the specific mutation, with more severe symptoms occurring at a younger age of onset. The most severe form of the disease occurs at birth, which can present with absence of bone mineralization in utero, resulting in stillbirth.
For the study, Millan, tested the hypothesis that, if a a bone-targeted form of the TNAP gene is administered from birth, then it would relieve the skeletal defects of HPP.
Thus, the researchers created a soluble form of human TNAP having a strong attraction to bone tissue. It was later injected into the fat layer under the skin of the mice, and it was found that the treated mice maintained a healthy rate of growth and apparent well being, as well as normal bone mineral density (BMD) of the skull, femur and spine. Also, they noticed complete preservation of skeletal and dental structures after 15 days, without any trace of bone lesions after 52 days of treatment.
“While the biochemical mechanism that leads to skeletal and dental defects of HPP is now generally understood. There is currently no established medical treatment,” said Millan.
After the success of this therapy, researchers are focused on reversing the bone defects in mice once the disease is quite advanced. Future clinical trials may reveal this as the first promising therapy for patients with this genetic disorder. (ANI)
- Promising results of gene therapy to treat eye diseases - Aug 14, 2010
- Potential treatment target for congenital heart disease identified - Feb 22, 2011
- Patient's own cells 'can be reprogrammed to correct genetic defects' - Apr 05, 2011
- First clinical trial of gene therapy offers muscular dystrophy clues - Oct 07, 2010
- Genetic switch that increases muscle blood supply identified - Mar 02, 2011
- Blame your genes for that stammer, says new study - Feb 21, 2011
- Gene therapy restores olfactory sense in mice - Sep 03, 2012
- Nine genes found to affect bone density - Aug 08, 2012
- Gene linked to congenital heart defect found - Dec 07, 2010
- Mouse genome offers human cancer clue - Mar 24, 2011
- Gene mutations help leukemia drug fight squamous cell lung cancer - Apr 04, 2011
- Fracture prone? Blame your genes - Apr 22, 2012
- Long-duration space flight 'is bad for the bones' - Nov 08, 2010
- Reasons behind kidney stones found - Apr 19, 2012
- Novel delivery device for gene therapy developed - Jul 07, 2010
Tags: biochemical mechanism, bmd, bone lesions, bone mineral density, bone mineralization, bone tissue, burnham institute for medical research, enzyme replacement therapy, femur, genetic origin, hypophosphatasia, jose luis millan, lack of vitamin d, phosphorus, rickets, skeletal defects, skeletal disease, stillbirth, tnap, utero